SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), announces a Materials Transfer Agreement (MTA) with HemoGenix®, a Contract Research Service Laboratory that provides a 21st-century approach to developing stem cell assays for the biotechnology and pharmaceutical industry. Their high-throughput, cost-effective technology imparts standardization of stem cell assays, making HemoGenix a valuable collaborator. As part of the agreement, ImmuneRegen will ship its therapeutic candidate Homspera® for testing using a number of proprietary tools developed and validated by HemoGenix.